Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Prison needle programs get a boost to fight HIV and hepatitis c

NCT ID NCT07122219

Knowledge-focused Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how to get more people in Canadian federal prisons to use needle exchange programs, which can help stop the spread of HIV and hepatitis C. Researchers will work in nine prisons, including five women's prisons, to find out what helps or hinders program use and put better strategies in place. About 548 incarcerated individuals will take part, with the goal of making these life-saving programs more effective and sustainable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 548 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All people incarcerated at a study site during the intervention period Exclusion Criteria: \- None (site level intervention)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis C virus (HCV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis C virus (HCV) HIV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atlantic Institution

    RECRUITING

    Smiths Crossing, New Brunswick, E9B 1T9, Canada

  • Dorchester Medium

    RECRUITING

    Dorchester, New Brunswick, E4K 2Y9, Canada

  • Edmonton Institution for Women

    NOT_YET_RECRUITING

    Edmonton, Alberta, T5S 2H9, Canada

  • Fraser Valley Institution for Women

    NOT_YET_RECRUITING

    Abbotsford British Columbia, British Columbia, V2S 1A1, Canada

  • Grand Valley Institution for Women

    NOT_YET_RECRUITING

    Kitchener, Ontario, N2P 2C5, Canada

  • Joliette Institution for Women

    NOT_YET_RECRUITING

    Joliette, Quebec, J6E 8W1, Canada

  • Joyceville Institution

    NOT_YET_RECRUITING

    Kingston, Ontario, K7L 4X9, Canada

  • Mission Institution

    NOT_YET_RECRUITING

    Mission, British Columbia, V2V 4L8, Canada

  • Nova Institution for Women

    RECRUITING

    Truro, Nova Scotia, B2N 6R8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.